Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.76 |
| ▸ | NPY2R | P49146 | 1/20 | 0.76 |
| ▸ | NPY4R | P50391 | 1/20 | 0.76 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.76 |
| ▸ | CXCR4 | P61073 | 8/20 | 0.74 |
| ▸ | PTH1R | Q03431 | 6/20 | 0.73 |
| ▸ | MC4R | P32245 | 1/20 | 0.73 |
| ▸ | MC5R | P33032 | 1/20 | 0.73 |
| ▸ | MC3R | P41968 | 1/20 | 0.73 |
| ▸ | MC1R | Q01726 | 1/20 | 0.73 |
| ▸ | TFPI | P10646 | 1/20 | 0.70 |
| ▸ | GLP1R | P43220 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29941416 | 0.99 | NPY1R (0.75) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| Acetic Acid SCHEMBL29399515 | 0.97 | NPY1R (0.75) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| Tosactide SCHEMBL29353880 | 0.95 | MC4R (0.77) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29587969 | 0.95 | GLP1R (0.73) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30578647 | 0.95 | GLP1R (0.73) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29519503 | 0.94 | MC4R (0.81) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29755703 | 0.94 | GLP1R (0.72) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30082666 | 0.93 | GLP1R (0.73) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29622934 | 0.92 | MC4R (0.83) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| Cosyntropin SCHEMBL15960130 | 0.92 | MC4R (0.81) | NPY1RNPY2RNPY4RNPY5RCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137558-A1 | OPHTHALMIC DEVICE | Able Tx Ltd. (IL) | 2026-05-21 | — | — | US | claimed |
| US-20260133154-A1 | ELECTROCHEMICAL SHOTGUN TAGGING ASSAY WITH CATALYTIC AMPLIFICATION | OXFORD UNIV INNOVATION LIMITED (GB) | 2026-05-14 | — | — | US | claimed |
| EP-3509584-B1 | GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT PANCREATIC CANCER | CORCEPT THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | claimed |
| US-12625150-B2 | Treatment of, and differential diagnosis between, ACTH-dependent Cushing's syndrome and ACTH-independent Cushing's syndrome | CORCEPT THERAPEUTICS INCORPORATED (US) | 2026-05-12 | — | — | US | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20260014235-A1 | METHODS OF PROMOTING REMYELINATION | COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION | 2026-01-15 | — | — | US | claimed |
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LTD (NZ) | 2025-12-04 | — | — | US | claimed |
| EP-4062917-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-12-03 | — | — | EP | claimed |
| EP-4076470-B1 | TREATMENT OF, AND DIFFERENTIAL DIAGNOSIS BETWEEN, ACTH-DEPENDENT CUSHING'S SYNDROME AND ACTH-INDEPENDENT CUSHING'S SYNDROME | CORCEPT THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| WO-2022173315-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2022-08-18 | — | — | WO | claimed |
| EP-4037713-A1 | INHIBITION OF THE VE-PTP PHOSPHATASE PROTECTS THE KIDNEY FROM ISCHEMIA-REPERFUSION INJURY | Northwestern University (US) | 2022-08-10 | — | — | EP | claimed |
| EP-3244878-B1 | SOLID ORAL DOSAGE FORMS | ENTERIS BIOPHARMA INC (US) | 2022-08-10 | — | — | EP | claimed |
| EP-4031004-A1 | DEVICE AND METHOD FOR PRE-TERM BIRTH RISK ASSESSMENT | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2022-07-27 | — | — | EP | claimed |
| CN-114774350-A | Method for preparing adenohypophysis or precursor tissue thereof | 国立研究开发法人理化学研究所 | 2022-07-22 | — | — | CN | claimed |
| US-20220163541-A1 | METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS WITH VASCULAR ENDOTHELIAL BIOMARKERS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2022-05-26 | — | — | US | claimed |
| CN-107075481-B | Method for preparing adenohypophysis or precursor tissue thereof | 国立研究开发法人理化学研究所 | 2022-05-17 | — | — | CN | claimed |
| CN-114470133-A | Composition for resisting psychogenic muscle tremor | 中国人民解放军空军军医大学 | 2022-05-13 | — | — | CN | claimed |
| US-20220111012-A1 | METHODS OF PROMOTING REMYELINATION | GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT | 2022-04-14 | — | — | US | claimed |
| EP-3973978-A1 | METHODS OF MODULATING CORTICOSTEROID RESPONSE | Mallinckrodt Ard IP Unlimited Company (IE) | 2022-03-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | NPY1R 396/4885NPY2R 116/4885NPY4R 402/4885 |
| US-20260014235-A1 | METHODS OF PROMOTING REMYELINATION | PMP22, MAG, CRH | NPY1R 335/4885NPY2R 297/4885NPY4R 379/4885 |
| US-20260137558-A1 | OPHTHALMIC DEVICE | IL2, ICOS, TRHDE | NPY1R 203/4885NPY2R 97/4885NPY4R 131/4885 |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | REN, AGT, FRS2 | NPY1R 2333/4885NPY2R 1758/4885NPY4R 2346/4885 |
| US-12625150-B2 | Treatment of, and differential diagnosis between, ACTH-dependent Cushing's syndrome and ACTH-independent Cushing's syndrome | MC2R, CRH, NR3C1 | NPY1R 231/4885NPY2R 209/4885NPY4R 264/4885 |
| US-20260133154-A1 | ELECTROCHEMICAL SHOTGUN TAGGING ASSAY WITH CATALYTIC AMPLIFICATION | BTD, APEX1, ACP1 | NPY1R 1796/4885NPY2R 3256/4885NPY4R 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.